TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic NPWT to Reduce SSI in Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ages 18-80~* patients who will undergo an open or laparoscopic-assisted clean/contaminated colorectal surgical procedure.~* Patients must either have an inflammatory bowel disease, undergoing reoperation within 30 days, or have two or more of the following risk factors: presence of an ostomy, type II diabetes, BMI greater than 30, immunosuppression, malnutrition, current smoker, chronic kidney disease (creatinine \> 1.2), and disseminated cancer.~Exclusion Criteria:~* patients currently enrolled in another interventional clinical trial,~* patients with a BMI less than 20, patients with a current abdominal abscess or infection (including a known urinary tract infection),~* patients allergic to or hypersensitive to silver, patients planning to undergo a second colorectal surgical procedure (e.g., colostomy or ileostomy takedown) or any other general surgery in less than 30 days of index-surgery,~* any patient in which the planned surgery would include: i) placement of a stoma in the principal incision; ii) placement of a drain into the supra-peritoneal fascia space that emerges through the principal incision; iv) placement of a drain into the intraperitoneal space that emerges through the principal incision; and v) supplementation of any of the irrigation fluid with antibiotic or antiseptic drugs,~* patients with healing disorders,~* pregnant women,~* prisoners, or~* any patient that is deemed unsuitable for the study by the Principal Investigator or the operating surgeon/Co-Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prevena (Type: EXPERIMENTAL): This group will receive the negative pressure wound therapy device.
- Standard of Care (Type: NO_INTERVENTION): This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of the Schiller BR-102 Plus PWA Device to Measure Central and Peripheral Hemodynamics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy individuals free of clinically relevant cardiovascular diseases or diabetes based on medical history and physical examination.~* Heart rhythm: Sinus rhythm~* Blood pressure range: 10 to 12 subjects in each of the three systolic blood pressure (SBP) and three diastolic blood pressure (DBP) recruitment ranges (low, medium, high).~Exclusion Criteria:~* Cardiac arrhythmia (atrial fibrillation, frequent extrasystoles)~* Pacemaker-dependent~* Pregnancy after the 6th month of the pregnancy~* Body mass index (BMI)\>30 kg/m2~* Known significant carotid or femoral artery stenosis~* Impalpable arterial pulse at site of measurement~* Age under 18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pulse wave analysis measurement (Type: EXPERIMENTAL): Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Helicobacter Pylori Genome Project (HpGP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~H. pylori strains collected from:~1. Adult aged 30 to 70 years old.~2. Patients who need upper endoscopy (examination of the lining of their stomach with a flexible tube).~3. Patients with stomach cancer.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Advanced intestinal metaplasia (Type: None): H. pylori strains from patients with:~* Complete-type intestinal metaplasia with extension to corpus, or~* Incomplete-type intestinal metaplasia of any extent
- Non-atrophic gastritis (Type: None): H. pylori strains from patients with non-atrophic gastritis
- Gastric cancer (Type: None): H. pylori strains from patients with gastric cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Perforator Vein Injection for Symptomatic Venous Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • The subject must be \> 18 years of age, male or female~  * Subject must be willing and able to wear compression stockings~ * Subject must have refluxing perforating veins ≥ 3.0 mm in diameter at the calf level or distally in the affected leg.~ * Subject presents with ulceration or other symptoms of venous stasis including:~rash, swelling, pain, bleeding, recurrent cellulitis~• The subject must sign a written informed consent, prior to randomization, using a form that is approved by the local Institutional Review Board.~Exclusion Criteria:~* • Pregnancy~  * Known allergy to STS~ * Refusal to wear compression stocking~ * Untreated significant great or small saphenous reflux~ * Disseminated malignancy or other terminal condition where subject is expected to live less than 6 months.~ * Significant arterial disease (ABI \< .8)~ * Buergers disease~ * Acute superficial thrombophlebitis~ * Phlebitis migrans~ * Acute cellulitis~ * Clinical evidence of active local or systemic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): None
- Injection + Compression (Type: EXPERIMENTAL): None
- Compression (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with pulmonary infection due to COVID-19, admitted in ICU and require mechanical ventilation or ECMO~* Male and female with Age\>18 years old~* Signed informed consent from patient or relatives~Exclusion Criteria:~* Pregnant or breast-feeding women~* Severe systemic disease (cancer, auto-immune etc) before infection accompanied by reduced life expectancy \<6 months~* Participation in another trial of an investigational drug or device~* Corticosteroid Use before initiation of treatment~* Sympathomimetic Use before initiation of treatment (epinephrine, norepinephrine, dobutamine, dopamine, phenylephrine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T3 solution for injection (Type: EXPERIMENTAL): T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
- Placebo (Type: PLACEBO_COMPARATOR): Composition identical apart from the active substance. Same dosage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient ≥ 18 years old~* Written informed consent obtained~* Patients who are planned to receive a lung transplant in the near future~* Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before screening visit and will continue to use a contraception method during the study~* The patient must be able to perform the lung monitoring at home~Exclusion Criteria:~* Pregnant or lactating female~* Known history of or active airways or anastomotic complications requiring intervention such as stenting or dilation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HRCT scans (Type: EXPERIMENTAL): High Resolution Computed Tomography scans will be taken

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Arthrodesis and Spinal Arthroplasty Database Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have had or will undergo a spinal arthrodesis and/or spinal arthroplasty procedure at Ohio State University~Exclusion Criteria:~* N/A

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- spinal arthrodesis and/or arthroplasty procedures (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male, age ≥18 years~2. Histologically confirmed castrate refractory metastatic adenocarcinoma of the prostate with progressive disease after surgical castration or during androgen suppression therapy including a GNRH agonist or antagonist and after at least 1 additional anti-hormonal manipulation; and serum testosterone level of \< 50 ng/dL or \< 1.7 nmol/L~   Progression will be confirmed either~  * radiologically or~  * by 2 consecutive rises of PSA, measured at least 1 week apart, resulting at least in a 50% increase over the nadir and a PSA \> 2 ng/mL.~  * An antiandrogen withdrawal response must have been excluded after discontinuation of antiandrogen therapy for at least 6 weeks.~3. Metastatic disease confirmed by imaging~4. ECOG performance status 0 or 1~Key Exclusion Criteria:~1. Previous immunotherapy for PCA (e.g. sipuleucel-T \[Provenge®\], experimental cancer vaccines or ipilimumab \[Yervoy®\]).~2. Treatment with any investigational anticancer agents within 4 weeks prior to first dose of study drug~3. Systemic treatment with immunosuppressive agents~4. Active skin disease (atopic eczema, psoriasis) in the areas for vaccine injection (upper arms or thighs) preventing the administration of i.d. injections into areas of healthy skin.~5. History of or current autoimmune disorders~6. Primary or secondary immune deficiency.~7. Seropositive for human immunodeficiency virus, hepatitis B virus (except after hepatitis B vaccination) or hepatitis C virus infection.~8. Symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable angina pectoris or myocardial infarction, significant cardiac arrhythmia, history of stroke or transient ischemic attack, all within 6 months prior to enrolment or severe hypertension according to WHO criteria or uncontrolled hypertension at the time of enrolment (systolic blood pressure ≥ 180 mm Hg)´~9. Previous chemotherapy for metastatic PCA.~10. Previous anti-hormonal treatment with abiraterone or any other investigational anti-hormonal treatment.~11. Cancer-related pain requiring opioid narcotics within 28 days before enrolment or an average pain score of \> 3 on a visual analogue scale.~12. Presence of visceral metastases.~13. History of other malignancies other than PCA over the last 5 years (except basal cell carcinoma of the skin).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CV9104 (Type: ACTIVE_COMPARATOR): CV9104 intradermal injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intradermal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (1 of the following):~* Completed insulin tolerance testing (ITT) at University of Michigan from 2012 to present.~* Are scheduled to complete ITT.~* Are clinically suspected to have adrenal insufficiency but have not undergone ITT.~Exclusion Criteria:~* Female patients who are of child-bearing potential (defined as a sexually mature woman who has not undergone hysterectomy, bilateral oophorectomy bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 12 weeks prior to screening, or who has not been naturally postmenopausal for at least 24 consecutive months prior to study enrollment) and not using non-hormonal contraception.~* Female patients not willing to use non-hormonal contraception for one month following treatment.~* Women who are pregnant or breast feeding.~* Patients with an existing diagnosis of adrenal insufficiency who are on any glucocorticoid replacement other than oral hydrocortisone or prednisone.~* Patients on medications that are strong CYP3A~* Patients taking other medications metabolized by CYP3A~* Patients who have a history of QT prolongation and patients with any recent abnormal electrocardiogram (ECG).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Patients will be provided a single dose of 600 milligram (mg) mifepristone to be administered orally, and subjects will be instructed to take the drug between 10PM and 11PM on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nasal HFOV Versus Nasal CPAP to Reduce Post-extubation pCO2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \<32+0 weeks~* Birth weight \<1500 g~* Received mechanical ventilation via an endotracheal tube for ≥120 h~* Caffeine treatment according to unit guidelines~* paCO2 \<65 mmHg with pH \>7.2~* FiO2 25-40% to maintain SpO2 at 90-94%.~* Time-cycled, pressure-controlled ventilation: PIP ≤22 cm H2O, PEEP ≤6 cm H2O; Volume guarantee ventilation: Working Ppeak ≤22 cm H2O, PEEP ≤6 cm H2O; High frequency oscillation ventilation: Pmean ≤12 cm H2O, Amplitude ≤30 cm H2O~* Decision of the attending clinician to extubate~Exclusion Criteria:~* Major congenital malformation requiring surgery~* Duct-dependent congenital heart disease~* Neuromuscular disease~* Participation in another randomized controlled trial~* Death before reaching the eligibility criteria~* Hydrocortisone treatment at the time of enrolment~* Chronological age \>28 days

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- nHFOV (Type: EXPERIMENTAL): Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
- nCPAP (Type: ACTIVE_COMPARATOR): Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of deep tissue Candida infection, defined as growth of Candida sp. from a culture specimen obtained from a normally sterile site accompanied by signs and symptoms of infection.~* Male or female ≥ 16 years of age.~* Expected hospitalization for at least fourteen (14) days.~Exclusion Criteria:~* Pregnancy or breast feeding or planning to become pregnant during the study.~* Recent treatment with one of the study drugs over the last 30 days.~* Allergy to either study drug or to this class of drugs.~* Significant liver dysfunction.~* Suspected Candida osteomyelitis, endocarditis, meningitis or any other infections of the central nervous system.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anidulafungin arm (Type: EXPERIMENTAL): None
- Caspofungin arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Press Fit Condylar (P.F.C.) Sigma Rotating-platform High-flexion (RP-F) Versus the Press Fit Condylar (P.F.C.) Sigma Rotating-platform (RP) Knee Implants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, aged between 45 and 75 years inclusive.~* Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.~* Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.~* Subjects who present with osteoarthritis that in the opinion of the clinical investigator requires a primary total knee arthroplasty.~* Subjects who in the opinion of the Clinical Investigator are considered to be suitable for treatment with either the P.F.C Sigma RP-F or the P.F.C Sigma RP knee, according to the indications specified in the package insert leaflet.~* Subjects who have authorised the transfer of his/her pseudonymised information to DePuy.~Exclusion Criteria:~* Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.~* Female subjects who are pregnant or lactating.~* Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.~* Subjects who have participated in a clinical investigation with an investigational product in the last month( 30 days).~* Subjects who are currently involved in any injury litigation claims.~* Subjects with a known history of poor compliance to medical treatment.~* Subjects who have previously had an osteotomy or significant surgery in the affected knee.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PFC Sigma RP-F (Type: OTHER): 125 patients to be allocated to this arm according to blinding envelopes
- PFC Sigma RP (Type: ACTIVE_COMPARATOR): 125 patients to be allocated to this arm according to blinding envelopes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues